Earnings summaries and quarterly performance for BIOCRYST PHARMACEUTICALS.
Executive leadership at BIOCRYST PHARMACEUTICALS.
Board of directors at BIOCRYST PHARMACEUTICALS.
Research analysts who have asked questions during BIOCRYST PHARMACEUTICALS earnings calls.
Brian Abrahams
RBC Capital Markets
4 questions for BCRX
Also covers: ACAD, ATAI, BIIB +17 more
Jessica Fye
JPMorgan Chase & Co.
4 questions for BCRX
Also covers: ALKS, ALNY, AMRN +23 more
Serge Belanger
Needham & Company
4 questions for BCRX
Also covers: AMPH, ARQT, CLSD +12 more
Stacy Ku
TD Cowen
4 questions for BCRX
Also covers: AUPH, KALV, RVNC +3 more
Huidong Wang
Barclays
3 questions for BCRX
Also covers: ALNY, BEAM, BLUE +15 more
Maurice Raycroft
Jefferies Financial Group
3 questions for BCRX
Also covers: ABEO, AFMD, ALNY +14 more
Tazeen Ahmad
Bank of America
3 questions for BCRX
Also covers: ACAD, ALNY, APLS +20 more
Jonathan Wolleben
JMP Securities, a Citizens Company
2 questions for BCRX
Also covers: ALT, CLSD, DBVT +5 more
Laura Chico
Wedbush Securities
2 questions for BCRX
Also covers: APLS, ARDX, BHVN +11 more
Liisa Bayko
Evercore ISI
2 questions for BCRX
Also covers: ALT, INSM, IPHA +7 more
Gena Wang
Barclays
1 question for BCRX
Also covers: ALNY, BLUE, BMRN +12 more
Jon Wolleben
Citizen JMP
1 question for BCRX
Also covers: CLSD, MDGL, MIRM +3 more
Maury Raycroft
Jefferies
1 question for BCRX
Also covers: ABEO, ALNY, ARWR +11 more
Seema Sheoran
Evercore ISI
1 question for BCRX
Steven Seedhouse
Raymond James
1 question for BCRX
Also covers: APLS, EDIT, GLMD +2 more
Steve Seedhouse
Cantor Fitzgerald
1 question for BCRX
Also covers: BOLD, HROW, VKTX +1 more
Recent press releases and 8-K filings for BCRX.
BioCryst Pharmaceuticals Updates on ORLADEYO Performance, Astria Acquisition, and Financial Outlook
BCRX
Guidance Update
M&A
Product Launch
- BioCryst Pharmaceuticals expects ORLADEYO revenue to be between $590-$600 million for the year, with a projected peak sales guidance of $1 billion by 2029.
- The company achieved its first year of profitability ahead of schedule and anticipates continued profitability even after the proposed acquisition of Astria.
- The proposed acquisition of Astria, which includes the late-stage HAE asset Nevenabart, is on track for a Q1 2026 closing. Nevenabart is anticipated to launch in late 2028.
- BioCryst completed the divestiture of its EU business for $250 million, which supported the Astria acquisition and improved the balance sheet.
- The company lowered its expense guidance from $440-$450 million to $430-$440 million.
Nov 19, 2025, 5:00 PM
BioCryst Pharmaceuticals Updates on ORLADEYO Sales, Astria Acquisition, and Financial Outlook
BCRX
Guidance Update
M&A
New Projects/Investments
- BioCryst Pharmaceuticals anticipates ORLADEYO sales of $590-$600 million for the current year and maintains its $1 billion peak sales guidance by 2029, supported by strong US growth and the expected pediatric indication approval. The company achieved profitability this year, a year ahead of schedule, and expects to sustain it.
- The company divested its EU business for $250 million, which was previously loss-making or break-even, to strengthen its balance sheet and facilitate the proposed acquisition of Astria Pharmaceuticals. This acquisition, on track for Q1 2026 closing, adds the late-stage HAE asset Nevenabart, projected to launch in the latter part of 2028.
- BioCryst has lowered its expense guidance from $440-$450 million to $430-$440 million for the current year, with expectations for significantly reduced expenses and higher operating profitability in 2027 and beyond.
- Upcoming pipeline catalysts include a PDUFA date on December 12 for ORLADEYO's pediatric indication and initial data for its Netherton Syndrome program (17725) by the end of Q1 next year.
Nov 19, 2025, 5:00 PM
BioCryst Pharmaceuticals Provides ORLADEYO Guidance, Updates on Astria Acquisition and Profitability
BCRX
M&A
Guidance Update
New Projects/Investments
- BioCryst Pharmaceuticals anticipates ORLADEYO revenue between $590-$600 million for the current year, with a projected $1 billion in peak sales by 2029, supported by strong US growth and the upcoming pediatric indication.
- The company completed an EU divestiture of ORLADEYO for $250 million, which strengthened its financial position and facilitated the proposed acquisition of Astria.
- The acquisition of Astria is on track to close in Q1 2026, adding the late-stage HAE asset Nevenabart, with a projected launch in late 2028 following top-line pivotal data in Q1 2027.
- BioCryst achieved its first year of profitability ahead of schedule and expects to maintain profitability, with lowered expense guidance to $430-$440 million.
Nov 19, 2025, 5:00 PM
BioCryst Presents Positive ORLADEYO Data and FDA Review Update for Pediatric HAE Treatment
BCRX
Product Launch
New Projects/Investments
Guidance Update
- BioCryst Pharmaceuticals announced new data from the APeX-P clinical trial, demonstrating early and sustained reductions in monthly HAE attack rates over one year in pediatric patients aged 2 to <12 years treated with once-daily ORLADEYO® (berotralstat) oral granules.
- Key findings from the trial include 65.5% of patients being attack-free at month 1 and 70.4% at month 12, with a median attack rate of 0 for 11 out of 12 months, and 93.1% of patients completing ≥48 weeks of treatment.
- The New Drug Application (NDA) for ORLADEYO oral granules for pediatric patients aged 2 to <12 years is under review with the U.S. FDA, with a target action date of December 12, 2025.
- If approved, ORLADEYO would be the first and only targeted oral prophylactic therapy for patients with HAE aged 2 to less than 12 years.
Nov 6, 2025, 1:00 PM
BioCryst Reports Strong Q3 2025 Results, Raises Guidance, and Announces Strategic Acquisitions and CEO Transition
BCRX
Earnings
Guidance Update
M&A
- BioCryst reported ORLADEYO revenue of $159.1 million for Q3 2025, representing 37% year-over-year growth, and raised its full-year 2025 ORLADEYO revenue guidance to between $590 million and $600 million. The company also lowered its non-GAAP operating expense guidance to $430-$440 million.
- The sale of BioCryst's European business was closed on October 1, enabling the full repayment of its Pharmakon debt. The company announced the proposed acquisition of Astria Therapeutics, expected to close in Q1 2026, and secured a strategic financing partnership with Blackstone for up to $400 million. BioCryst reported non-GAAP operating profit of $51.7 million and non-GAAP net income of $35.6 million for Q3 2025, ending the quarter with a pro forma cash balance of approximately $294 million and zero term debt.
- In pipeline updates, early data for the DME program is expected early next year, after which BioCryst plans to spin out or partner the program. For BCX-17725 in Netherton syndrome, encouraging healthy volunteer data showed drug distribution to the skin, with early patient data now expected later in Q1 next year. Additionally, Charlie Gayer will transition to CEO on January 1, with Ron Dellinger becoming Chief Commercial Officer.
Nov 3, 2025, 1:30 PM
BioCryst Reports Strong Q3 2025 ORLADEYO Growth and Announces Astria Acquisition
BCRX
Earnings
Guidance Update
M&A
- BioCryst reported ORLADEYO revenue growth of +37% year-over-year for Q3 2025 and raised its FY25 guidance range to $590-600 million.
- The company announced the acquisition of Astria for approximately $700 million Total Enterprise Value, comprising an equity portion of ~$280 million and a cash portion of ~$420 million, with expectations to remain profitable and cash flow positive post-transaction.
- As of September 30, 2025, BioCryst held $269 million in cash, cash equivalents, restricted cash & investments, with a pro forma cash position of $294 million.
- Initial data from Part 3 of the BCX17725 Phase 1 trial for Netherton syndrome patients is anticipated by the end of Q1 2026.
Nov 3, 2025, 1:30 PM
BioCryst Reports Strong Q3 2025 Results and Raises Full-Year Guidance
BCRX
Earnings
Guidance Update
M&A
- BioCryst reported Q3 2025 ORLADEYO net revenue of $159.1 million, representing a 37% year-over-year increase.
- The company achieved Q3 2025 GAAP operating profit of $29.6 million and non-GAAP operating profit of $51.7 million.
- Net income for Q3 2025 was $12.9 million ($0.06 per share), with non-GAAP net income at $35.6 million ($0.17 per share).
- BioCryst raised its full-year 2025 ORLADEYO net revenue guidance to between $590 million and $600 million and lowered its non-GAAP operating expense guidance to between $430 million and $440 million.
- Strategic developments include the completion of the European ORLADEYO business sale, which retired all remaining Pharmakon term debt, and a definitive agreement to acquire Astria Therapeutics, expected to close in Q1 2026.
Nov 3, 2025, 12:13 PM
BioCryst Announces Acquisition of Astria Therapeutics
BCRX
M&A
New Projects/Investments
- BioCryst announced its intent to acquire Astria Therapeutics for a total enterprise value of approximately $700 million.
- The acquisition implies a value of $13 per share in cash and stock for Astria stockholders, who are expected to own 15% of proforma equity.
- This transaction is expected to expand and strengthen BioCryst's presence in HAE, transform its revenue growth profile, and be significantly accretive to operating profit (non-GAAP) in the first full year of launch.
- BioCryst anticipates remaining profitable (non-GAAP) and cash flow positive post-transaction, with an expected cash balance of $1B+ by 2029.
- The transaction is expected to close in Q1 2026.
Oct 14, 2025, 12:00 PM
BioCryst Pharmaceuticals to Acquire Astria Therapeutics
BCRX
M&A
New Projects/Investments
Guidance Update
- BioCryst Pharmaceuticals announced the acquisition of Astria Therapeutics, adding the late-stage hereditary angioedema (HAE) compound Nevenibart to its pipeline.
- This strategic move aims to leverage BioCryst's existing commercial engine for rare diseases, with Nevenibart offering potential every three to six month dosing for HAE patients, addressing an unmet need for less burdensome treatment.
- The combined HAE portfolio, including ORLADEYO (projected to reach $1 billion at peak), is expected to drive double-digit annual revenue growth to at least $1.8 billion by 2033.
- The transaction, expected to close in Q1 2026, will be financed with BioCryst equity and up to $400 million in cash from Blackstone, and is anticipated to be significantly accretive to operating profit with minimal incremental SG&A investment.
- Top-line data for Nevenibart is expected in early 2027.
Oct 14, 2025, 12:00 PM
BioCryst Pharmaceuticals announces acquisition of Astria Therapeutics
BCRX
M&A
New Projects/Investments
Guidance Update
- BioCryst Pharmaceuticals, Inc. (BCRX) announced the acquisition of Astria Therapeutics, Inc. for an implied enterprise value of approximately $700 million, with the transaction expected to close in the first quarter of 2026.
- The acquisition adds navenibart, a late-stage, long-acting plasma kallikrein inhibitor in Phase 3 clinical development for hereditary angioedema (HAE) prophylaxis, with top-line data expected in early 2027.
- BioCryst expects to remain profitable (non-GAAP) and cash flow positive post-transaction, and has secured a $550 million strategic financing facility from Blackstone to fund a portion of the cash consideration.
- Astria stockholders will receive $8.55 in cash and 0.59 shares of BioCryst common stock per share, representing an implied value of $13.00 per Astria share, and will own approximately 15% of proforma equity in the combined company.
Oct 14, 2025, 11:10 AM
Quarterly earnings call transcripts for BIOCRYST PHARMACEUTICALS.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more